The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow The Top 25 Broker Analyst Picks of the S&P 500

By The Online Investor Staff, updated Tue., Sep. 23, 6:19 AM

#25 of the S&P 500: Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s products include Stribild, Complera/Eviplera, Truvada® and Vitekta for human immunodeficiency virus; Viread and Hepsera® for liver diseases; Letairis®, Ranexa®, and Lexiscan/Rapiscan® for cardiovascular; and Cayston® and Tamiflu® for respiratory. Co.'s other products include AmBisome®, to treat fungal infections; Vistide®, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen®, an intravitreal injection of an anti-angiogenic oligonucleotide for the treatment of neovascular age-related macular degeneration.
Open the GILD Page at The Online Investor »

Company Name:  Gilead Sciences, Inc.
Website:  www.gilead.com
Sector:  Biotechnology
Number of ETFs Holding GILD:  87
Total Market Value Held by ETFs:  $7.99B
Total Market Capitalization:  $160.13B
% of Market Cap. Held by ETFs:  4.99%

Open the GILD Page at The Online Investor (in a new window) »

September 23, 2014    6:19 AM Eastern

Strong Buy (3.67 out of 4)
81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite
Quotes delayed 20 minutes



Strong Buy (3.67 out of 4)
81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

The Top 25 Broker Analyst Picks of the S&P 500 - Slide 1 of 25 | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.